Showing 4441-4450 of 5771 results for "".
- Russia Says COVID-19 Vaccine Sputnik V 92% Effective in Late-Stage Studyhttps://modernod.com/news/russia-says-covid-19-vaccine-sputnik-v-92-effective-in-late-stage-study/2478524/Interim results from a phase 3 study of the Gamaleya Institute’s COVID-19 vaccine Sputnik V suggest that it had an efficacy rate of 92% after the second dose, the Russian Direct Investment Fund (RDIF) announced Wednesday. The data come after 20 confirmed cases of coronavirus were recorded 2
- Santen to Present Glaucoma/OcularHypertension Data at AAO 2020 Virtualhttps://modernod.com/news/santen-to-present-glaucoma-ocularhypertension-data-at-aao-2020-virtual/2478519/Santen announced that the following talks on glaucoma and ocular hypertension will be presented at the American Academy of Ophthalmology (AAO) Virtual 2020 meeting. Poster Topic: MicroShunt (or DE-128), an investigational surgical glaucoma implant designed to reduce intrao
- Bausch + Lomb Highlights Surgical, Pharmaceuticals and Consumer Health Care Innovations at AAO 2020 Virtual Meetinghttps://modernod.com/news/bausch-lomb-highlights-surgical-pharmaceuticals-and-consumer-health-care-innovations-at-aao-2020-virtual-meeting/2478521/Bausch + Lomb announced plans to highlight its latest surgical, pharmaceuticals and consumer health care innovations, as well as several new business ventures, at the company’s virtual exhibit booth during the annual meeting of the American Academy of Ophthalmology (AAO), which takes place Nov. 1
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- Topology Introduces Proprietary Touchless Optical Platform (TOP)https://modernod.com/news/topology-introduces-proprietary-touchless-optical-platform-top/2478518/Topology announced the introduction of their proprietary Touchless Optical Platform (TOP), a technology platform aimed at improving the optical experience for patients and staff, while driving incremental revenue. With the Touchless Optical Platform, Eyewear sales are generated seamlessly,
- Lensar to Present Several Papers at 2020 AAO Virtual Meetinghttps://modernod.com/news/lensar-to-presents-several-papers-at-2020-aao-virtual-meeting/2478513/Lensar announced the following posters/papers were accepted to be presented at the 2020 AAO Virtual Meeting taking place Nov. 13-15. 2020 AAO Accepted Posters/Papers Company Ty
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p
- FDA Authorizes Lilly’s Antibody Therapy Bamlanivimab for Recently Diagnosed COVID-19https://modernod.com/news/fda-authorises-lillys-antibody-therapy-bamlanivimab-for-recently-diagnosed-covid-19/2478512/Eli Lilly announced Monday that the FDA has granted its emergency-use authorization (EUA) request for the investigational neutralizing antibody bamlanivimab. The AbCellera-partnered therapy, also known as LY-CoV555, is authorized to treat recently diagnosed, mild-to-moderate COVID-19 in patients
- Allergan to Share New Data at American Academy of Ophthalmology (AAO) 2020 Virtual Meetinghttps://modernod.com/news/allergan-to-share-new-data-at-american-academy-of-ophthalmology-aao-2020-virtual-meeting/2478510/Allergan, which is now part of AbbVie, announced that it will present new data advancing scientific understanding of an IOP-lowering treatment in glaucoma and evaluating an investigational treatment for presbyopia at American Academy of Ophthalmology (AAO) 2020 virtual meeting (November 13-15).</
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of